...plays a role in establishing hair cell identity during development. Frequency Therapeutics Inc. (NASDAQ:FREQ) and Sound Pharmaceuticals...
...hearing disorders. “There are things we learned from it,” Jonathan Kil, CEO and CMO of Sound Pharmaceuticals...
...fail because the supporting cell cannot be manipulated like that in the adult.” Jonathon Kil, Sound Pharmaceuticals...

...$0.06 on Friday to end the week at $2.19. Sound’s therapy improves hearing in Meniere Sound Pharmaceuticals...
...Tone Audiometry, meeting a primary efficacy endpoint. The selenium-based small molecule, a GPX mimic containing ebselen...

...mutant complexed with a library of cysteine-reactive compounds identified the NFE2L2 activator ebselen and an ebselen...
...normal SOD1 folding and testing them in transgenic mouse models of ALS. Sound Pharmaceuticals Inc. has ebselen...
...Inc. has ebselen (SPI-1005) in Phase II testing for hearing loss and Meniere’s disease, and ebselen...

...In October, Sound Pharmaceuticals Inc. (Seattle, Wash.) reported top-line data from a Phase Ib trial in 40...
...data from a Phase Ib trial in 40 patients with Meniere’s disease showing that oral ebselen...
...product is in Phase IIb testing to treat Meniere’s disease. Sound Pharmaceuticals Inc., Seattle, Wash. Product: Ebselen...

...Sound Pharmaceuticals Inc. (Seattle, Wash.) began the double-blind, placebo-controlled Phase IIb SPI-1005-251 trial of ebselen (SPI-1005...
...that activates nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2). Sound Pharmaceuticals Inc. , Seattle, Wash. Product: Ebselen...
...disease Endpoint: Safety and hearing loss, tinnitus and vertigo Status: Phase IIb started Milestone: NA Allison Johnson SPI-1005 Sound Pharmaceuticals...

...we've come to recognize two new potential pathways of treating hearing loss." David Weber, Otonomy Sound Pharmaceuticals...
...in 4Q18 for SPI-5557 to treat severe to profound hearing loss. The company’s lead program, ebselen...
...Healthcare Systems Inc., Boston, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Sound Pharmaceuticals...

...twice daily for 21 days in about 40 patients. Sound Pharmaceuticals Inc. , Seattle, Wash. Product: Ebselen...

...Infectious disease INDICATION: Clostridium In vitro and mouse studies suggest ebselen could be repurposed to treat...
...ebselen decreased toxicity and increased survival compared with vehicle. In a mouse model of CDI, ebselen...
...Next steps could include testing ebselen in additional animal models of CDI. Sound Pharmaceuticals Inc. has ebselen...

...molecule Formulation of the generic steroid dexamethasone Hearing loss associated with Meniere's disease Phase II Sound Pharmaceuticals...
...chemotherapy-induced hearing loss Preclinical Oricula Therapeutics LLC BPN-13661 Small molecule Undisclosed Antibiotic-induced hearing loss Preclinical Sound Pharmaceuticals...

...III trials to prevent hearing loss associated with platinum-based chemotherapy in children. Sound Pharmaceuticals Inc. has Ebselen...